Consideration of Entry in Europe to leverage partnering negotiations

Situation

• US Biopharmaceutical with ambition to become a global organization
• First major product for the company, extremely promising for a high unmet need indication

Bionest Contribution

Detailed work that evaluated:

• Potential for the product in Europe, including clinical practices, epidemiological factors and competition
• Sizing of the required infrastructure to support the launch in Europe
• Methodology to maximize value from the partnering process

Key Results

• Extensive analysis and preparation of range of options allowed our client to be ‘in the driving seat’ for partnering negotiations
• Company signed one of the largest biotech-big pharma deals for the European rights of its product. Value was driven by understanding of product potential, product positioning, and consequently leading partnering process